Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of viral therapy in treating
young patients with solid tumors that have come back or that have not responded to standard
therapy. Some tumors have cells with a genetic weakness that makes them unable to fight off a
virus called wild-type reovirus. The virus causes cells with this weakness to die, and may
therefore be able to kill tumor cells without damaging normal cells. Cyclophosphamide is a
drug used in chemotherapy that stops tumor cells from dividing and causes them to die. Giving
wild-type reovirus together with cyclophosphamide may kill more tumor cells.